Clinical Trials Logo

Clinical Trial Summary

The aim of this study are to evaluate the feasibility of needle knife fistulotomy (NKF) as an initial procedure for biliary access in patients with biliary disease who are at increased risk for post-endoscopic retrograde endoscopic retrograde cholangiopancreatography (PEP) and to assess the incidence rate of complications including PEP between NKF and conventional cannulation methods.


Clinical Trial Description

Endoscopic retrograde endoscopic retrograde cholangiopancreatography (ERCP) is widely used for the diagnosis and treatment of pancreatic and biliary tract disease. However, post-ERCP pancreatitis (PEP) is the most common adverse event following the procedure, ranging from 2% to 10% in nonselective cases, and it can cause substantial morbidity, mortality, or high medical costs. Recent advances in cannulation technique and accessories for biliary cannulation have contributed to reduce the incidence of PEP, but biliary cannulation can fail in 5% to 20% of cases of ERCP. Suprapapillary needle-knife fistulotomy (NKF), with or without large-diameter balloon dilation, has been used as a rescue method in cases of difficult biliary cannulation, and NKF was recommended as an initial approach to selective biliary cannulation in cases of repetitive unintentional pancreatic cannulation.9 Moreover, difficult biliary cannulation is known to be a risk factor for PEP, and it has been reported that NKF is associated with a low risk of PEP. Thus, we hypothesized that NKF may reduce the risk of PEP in patients who are at increased risk for PEP. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02916199
Study type Interventional
Source Gangnam Severance Hospital
Contact
Status Completed
Phase N/A
Start date October 4, 2016
Completion date November 28, 2017

See also
  Status Clinical Trial Phase
Recruiting NCT04205058 - Coffee After Pancreatic Surgery N/A
Completed NCT02971579 - A Register on the Quality of ERCP and Training of Endoscopists in Italy
Not yet recruiting NCT01900938 - Comparison Between Continuous Infusion and Intermittent Bolus Injection of Propofol for Deep Sedation During ERCP N/A
Completed NCT01427725 - Special Investigation of LipaCreon on Long-term Use in Patients With Pancreatic Exocrine Insufficiency
Not yet recruiting NCT05954221 - Red Cell Lysis Buffer Application Versus Conventional Sample Processing in EUS-FNB N/A
Enrolling by invitation NCT02471170 - Protocol to Permit the Acquisition of Circulating Tumor Material in Pancreatic Diseases
Completed NCT04705740 - Influence of the Endoscopists and Endoscopic Retrograde CholangioPanceratography
Recruiting NCT04259580 - Calgary Registry for Advanced and Therapeutic Endoscopy
Recruiting NCT04291651 - UCSF PANC Cyst Registry
Enrolling by invitation NCT03234543 - Remote Ischemic Conditioning in Abdominal Surgery N/A
Completed NCT03717298 - Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma Phase 2
Recruiting NCT03334708 - A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma
Recruiting NCT05249400 - Effect of Off-site Assistance on Success Rate of Selective Cannulation During hands-on ERCP Training N/A
Recruiting NCT05824403 - PAncreatic Disease Cohort of TOuLouse
Active, not recruiting NCT03269994 - Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy? Phase 3
Enrolling by invitation NCT04329039 - Somatostatin Analogues With Perioperative Antibiotics Versus Prolonged Antibiotics Phase 2/Phase 3
Completed NCT03198871 - IV Acetaminophen for Post-Operative Pain Management in Enhanced Recovery After Surgery (ERAS) Population Phase 4
Completed NCT02337673 - Screening of Postoperative Pulmonary Complications by Electrical Impedance Tomography
Completed NCT01964430 - Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Phase 3
Completed NCT02739074 - Effectiveness of Metal Protheses Covered in "Diabolo" in Treatment of Necrosis of Origin Pancreatic: Trial "DIABOLOPIG"